晚期胃食管肿瘤的新治疗选择：是否适用于当前临床实践？
New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?
作者信息
Puhr Hannah Christina, Preusser Matthias, Prager Gerald, Ilhan-Mutlu Aysegül
机构信息
Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Comprehensive Cancer Center Vienna-Gastroesophageal Tumors Unit, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
出版信息
Cancers (Basel). 2020 Jan 28;12(2):301. doi: 10.3390/cancers12020301.
Abstract
Several clinical trials attempted to identify novel treatment options for advanced gastroesophageal tumours in first, second and further lines. Although results of targeted therapy regimens were mainly disappointing, novel immunotherapy agents showed promising activity, which led to their approval in second and third lines in many countries. This review focuses on the results of recent clinical trials investigating novel agents including targeted therapies, immunotherapy components and chemotherapies and discuss their current impact as well as current approval status on the treatment armamentarium of advanced gastroesophageal tumours.
摘要
多项临床试验试图确定一线、二线及后续治疗中晚期胃食管肿瘤的新治疗方案。尽管靶向治疗方案的结果大多令人失望，但新型免疫治疗药物显示出了有前景的活性，这使得它们在许多国家被批准用于二线和三线治疗。本综述重点关注近期临床试验中研究新型药物（包括靶向治疗、免疫治疗成分和化疗）的结果，并讨论它们目前对晚期胃食管肿瘤治疗手段的影响以及当前的获批情况。
相似文献
1
New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?晚期胃食管肿瘤的新治疗选择：是否适用于当前临床实践？
Cancers (Basel). 2020 Jan 28;12(2):301. doi: 10.3390/cancers12020301.
2
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.检查点抑制剂在食管癌和胃癌治疗中的作用。
Cancers (Basel). 2023 Aug 14;15(16):4099. doi: 10.3390/cancers15164099.
3
Role of Immunotherapy in Advanced Gastroesophageal Cancer.免疫疗法在晚期胃食管交界处癌中的作用。
Curr Oncol Rep. 2020 Aug 17;22(11):112. doi: 10.1007/s11912-020-00975-y.
4
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.晚期/转移性胃癌或胃食管结合部癌患者在不同治疗线的真实世界治疗模式和临床结局。
Clin Colorectal Cancer. 2020 Mar;19(1):32-38.e3. doi: 10.1016/j.clcc.2019.09.001. Epub 2019 Sep 24.
5
Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer.局部晚期食管癌全身治疗的最新进展
Cancers (Basel). 2023 Mar 22;15(6):1900. doi: 10.3390/cancers15061900.
6
Emerging Therapies in the Management of Advanced-Stage Gastric Cancer.晚期胃癌治疗中的新兴疗法
Front Pharmacol. 2018 Sep 13;9:404. doi: 10.3389/fphar.2018.00404. eCollection 2018.
7
Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?晚期胃癌或胃食管交界癌（GC/GEJC）治疗的新前沿：免疫疗法会成为未来的方向吗？
Front Oncol. 2020 Jul 21;10:912. doi: 10.3389/fonc.2020.00912. eCollection 2020.
8
Current and future roles of targeted therapy and immunotherapy in advanced melanoma.靶向治疗和免疫疗法在晚期黑色素瘤中的当前和未来作用。
J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. doi: 10.18553/jmcp.2014.20.4.346.
9
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy.晚期食管胃结合部癌的治疗进展和免疫治疗的作用日益凸显。
Expert Rev Anticancer Ther. 2021 May;21(5):535-546. doi: 10.1080/14737140.2021.1866548. Epub 2021 Jan 11.
10
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.检查点抑制剂治疗转移性胃癌的演进：现状与未来展望。
Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22.
引用本文的文献
1
Tumor vessel normalization and immunotherapy in gastric cancer.胃癌中的肿瘤血管正常化与免疫治疗
Ther Adv Med Oncol. 2022 Jul 18;14:17588359221110176. doi: 10.1177/17588359221110176. eCollection 2022.
2
Solasonine induces apoptosis of the SGC-7901 human gastric cancer cell line in vitro via the mitochondria-mediated pathway.皂角苷通过线粒体介导的途径诱导体外 SGC-7901 人胃癌细胞凋亡。
J Cell Mol Med. 2022 Jun;26(12):3387-3395. doi: 10.1111/jcmm.17343. Epub 2022 May 7.
3
Gastric cancer risk-scoring system based on analysis of a competing endogenous RNA network.基于竞争性内源性RNA网络分析的胃癌风险评分系统
Transl Cancer Res. 2020 Jun;9(6):3889-3902. doi: 10.21037/tcr-19-2977.
4
Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.阿帕替尼联合S-1用于既往接受过治疗的晚期胃或胃食管交界腺癌：一项2期单臂前瞻性研究。
J Gastrointest Oncol. 2021 Oct;12(5):2035-2044. doi: 10.21037/jgo-21-186.
本文引用的文献
1
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).雷戈非尼联合纳武利尤单抗治疗晚期胃或结直肠癌患者的开放标签、剂量递增和剂量扩展Ib 期临床试验（REGONIVO，EPOC1603）。
J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28.
2
A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.三药联合化疗与两药联合化疗改善晚期胃癌患者生存的比较：系统评价和荟萃分析。
BMC Cancer. 2019 Nov 20;19(1):1125. doi: 10.1186/s12885-019-6294-9.
3
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.接受胃切除术的转移性胃癌患者接受替氟尿苷/替匹嘧啶治疗的疗效和安全性：一项随机临床试验的亚组分析。
JAMA Oncol. 2020 Jan 1;6(1):e193531. doi: 10.1001/jamaoncol.2019.3531. Epub 2020 Jan 9.
4
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者（ATTRACTION-3）：一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
5
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.胃癌中微卫星不稳定性作为生物标志物价值的个体化患者数据汇总分析。
J Clin Oncol. 2019 Dec 10;37(35):3392-3400. doi: 10.1200/JCO.19.01124. Epub 2019 Sep 12.
6
Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.同步转移性胃食管交界癌患者一线姑息性全身治疗的异质性：一项真实世界证据研究。
Int J Cancer. 2020 Apr 1;146(7):1889-1901. doi: 10.1002/ijc.32580. Epub 2019 Aug 24.
7
More is not always better: triplet chemotherapy and advanced gastric cancer.更多并不总是更好：三联化疗与晚期胃癌
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):490-491. doi: 10.1016/S2468-1253(19)30145-1. Epub 2019 May 14.
8
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗（FLOT4）：一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
9
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.帕博利珠单抗单药或联合化疗作为晚期胃或胃食管结合部腺癌患者的一线治疗：来自 II 期非随机 KEYNOTE-059 研究的结果。
Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.
10
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.KEYNOTE-590：帕博利珠单抗联合或不联合化疗一线治疗晚期食管癌的 III 期研究。
Future Oncol. 2019 Apr;15(10):1057-1066. doi: 10.2217/fon-2018-0609. Epub 2019 Feb 8.
Zotero 插件